As in previous editions, Biocat was coordinating the participation in Biospain 2016 of the delegation of the BioRegion of Catalonia. The fair is the largest biotechnology event in Europe to be organized by a national bioindustry association and one of the most important in the world, due to the number of one-to-one meetings (more than 3,000 in each edition), as well as the number of companies participating (over 850). Thirty-four percent of the delegates come from outside Spain. In 2016, Bilbao was hosting the fair that took place from 28 to 30 September and which was attended by nearly 90 Catalan companies.
Biospain has become the most important biotechnology event in Europe with a fixed base in one country and the fifth in the ranking worldwide, due to the number of business development meetings.
The eighth edition of Biospain gathered 220 exhibitors, over 1,500 delegates from 28 countries and 700 companies and institutions. This edition was special because for the first time the partnering booths and conference halls were inside the same Trade Fair pavilion, thus making it easier to move between the different areas; consequently increasing the movement of the people were visiting the fair.
Nearly 90 Catalan businesses and entities participated in the fair, of which five (Iproteos, Mind the Byte, Ability Pharma, Enantia and Specipig) had a significant role inside the business pavilion coordinated by Biocat, with said companies occupying an area of 28 m2 (A3-A5/B2-B4).
Below is the list of Catalan companies that attended the fair:
Biospain was organized like a trade fair and features a partnering area, investor forum, training and employment forum, conferences on diverse subjects (parallel sessions) with national and International speakers and the scientific congress offered by scientific partnerships.
Close to 50 Spanish & international investors and pharma in-licensing teams attended: Ysios Capital Partners, Edmond de Rothschild Investment Partners, Gilde Healthcare, BioGeneration Ventures, Forbion Capital Partners, Cross Road Biotech, Lumira Capital, Seventure Partners, Lundbeckfonden Ventures, Capricon Ventures, Chugai Pharmaceutical, GlaxoSmithKline, Johnson & Johnson Innovation, Merck Ventures, Novartis Ventures Fund, Roche, Sanofi Pharmaceuticals and many more.
Albert Barberà, CEO of Biocat, participated as a speaker to this talk moderated by Ernest Lara (from the Richi Foundation) on Wednesday 29th of September. In this session, the main representatives of organizations responsible for fostering health ecosystems in Massachusetts, Spain, Basque Country and Catalonia debated about best practices to make the most out of local resources (talent, capital, technology and networks). They also shared opinions about what to do to accelerate their growth, as well as to strengthen the innovation bridge between Massachusetts and Spain.
Biocat also had presence in the Biotechnology Career Fair hosting Biospain through its program Design Health Barcelona (d·Health Barcelona), the first master in biodesign taught in our country and aims to promote innovation in health, entrepreneurship and professional development in the biomedical field.